Tivantinib (ARQ 197) is the first non-ATP-competitive c-Met inhibitor with Ki of 0.355 ?M in a cell-free assay, little activity to Ron, and no inhibition to EGFR, InsR, PDGFR? or FGFR1/4. Phase 3.
choosing a selection results in a full page refresh
Product has been added to your wishlist.
You can view your wishlist by creating or login account.
Please create account through ##customer_email## email
